NovaBay Pharmaceuticals, Inc. (NBY) released its Q2 2026 results showing no recent pharmaceutical revenue updates and continued net losses. The company has rebranded to Stablecoin Development Corporation and currently holds approximately 2.30 billion SKY tokens, engaging actively in on-chain staking activities. Despite strong liquidity with nearly $7 million in cash and a high current ratio, operating metrics indicate financial sustainability challenges typical of biotech firms but compounded by strategic shifts away from core pharmaceutical development. The absence of disclosed clinical trial progress or product commercialization updates obscures visibility into the company’s traditional business model, while the pivot towards blockchain suggests an evolving—but unproven—revenue mechanism.